SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences’ arm launches Topiramate Extended-Release Capsules

06 Jan 2023 Evaluate

Zydus Lifesciences’ U.S. subsidiary -- Zydus Pharmaceuticals (USA) Inc. has launched Topiramate Extended-Release Capsules. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg (USRLD: Trokendi XR). Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.

Topiramate Extended-Release capsule is indicated for Epilepsy: initial monotherapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset, primary generalized tonic-clonic seizures, or seizures associated with Lenox-Gastaut Syndrome (LGS). It is also indicated for prophylaxis of migraine in patients 12 years of age and older. Topiramate Extended-Release capsule had annual sales of USD 488mn in the United States according to IQVIA data (IQVIA MAT Nov. 2022).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

941.25 -1.30 (-0.14%)
20-Apr-2026 13:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.70
Dr. Reddys Lab 1236.80
Cipla 1232.00
Zydus Lifesciences 941.25
Lupin 2334.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×